(1 - 20 von 27
)
Business Wiremoneyspecial.de
www.moneyspecial.de
... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. "The FDA's granting of a priority review further reinforces the Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. "The FDA's granting of a priority review further reinforces the ...
News - Full StoryTickerTech.com
www.tickertech.com
... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. "The FDA's granting of a priority review further reinforces the Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. "The FDA's granting of a priority review further reinforces the ...
2021's Fiercest Women in Life SciencesBioscienceLA
www.biosciencela.org
— Or Nia Tatsis, who rarely saw other women in academia during her training but now ensures the next generation will because of diversity — Or Nia Tatsis, who rarely saw other women in academia during her training but now ensures the next generation will because of diversity ...
Exa-Cel May Soon Be Approved for Patients in the EURare Disease Advisor
www.rarediseaseadvisor.com
— ... Nia Tatsis, PhD, executive vice president and chief regulatory and quality officer at Vertex. Exa-cel is in the process of becoming the only — ... Nia Tatsis, PhD, executive vice president and chief regulatory and quality officer at Vertex. Exa-cel is in the process of becoming the only ...
FDA accepts NDA for Vertex's non-opioid pain drugPharmaNewsIntel
pharmanewsintel.com
— ... Nia Tatsis, PhD, Executive Vice President, Chief Regulatory and Quality Officer at Vertex, in the press release. “The FDA's granting of a — ... Nia Tatsis, PhD, Executive Vice President, Chief Regulatory and Quality Officer at Vertex, in the press release. “The FDA's granting of a ...
FDA accepts NDA for suzetrigine for the treatment of ...Medthority
www.medthority.com
— ... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. “The FDA's granting of a priority review — ... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. “The FDA's granting of a priority review ...
FDA decision on Vertex's non-opioid analgesic suzetrigine ...FirstWord Pharma
firstwordpharma.com
— Highlighting “the high unmet need in treating acute pain” and the “known risks, including addictive potential” of opioids, Nia Tatsis, chief — Highlighting “the high unmet need in treating acute pain” and the “known risks, including addictive potential” of opioids, Nia Tatsis, chief ...
FDA decision on vanza triple, new CFTR modulator, due by ...Cystic Fibrosis News Today
cysticfibrosisnewstoday.com
— ... Nia Tatsis, PhD, executive vice president, chief regulatory and quality officer at Vertex, said in a company press release. CF is caused by — ... Nia Tatsis, PhD, executive vice president, chief regulatory and quality officer at Vertex, said in a company press release. CF is caused by ...
FDA to Review Vertex Pharma's NDA for 'Vanza Triple ...Precision Medicine Online
www.precisionmedicineonline.com
— ... Nia Tatsis, Vertex's executive VP and chief regulatory and quality officer, said in a statement. Vertex has also submitted regulatory — ... Nia Tatsis, Vertex's executive VP and chief regulatory and quality officer, said in a statement. Vertex has also submitted regulatory ...
News - A | Self Directed Investorselfdirectedinvestor.com
www.selfdirectedinvestor.com
— ... Nia Tatsis, Ph.D., and Jodie Morrison to its board of directors. Dr. Tatsis currently serves as executive vice president, chief regulatory — ... Nia Tatsis, Ph.D., and Jodie Morrison to its board of directors. Dr. Tatsis currently serves as executive vice president, chief regulatory ...
Vertex Announces FDA Acceptance of New Drug ...AFP.com
www.afp.com
— ... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. “The FDA's granting of a priority review — ... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. “The FDA's granting of a priority review ...
Vertex Announces FDA Acceptance of New Drug ...Morningstar
www.morningstar.com
— ... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. “Vanzacaftor raises the high bar set by — ... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. “Vanzacaftor raises the high bar set by ...
Vertex Announces FDA Acceptance of New Drug ...ReachMD
reachmd.com
— ... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. "The FDA's granting of a priority review — ... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. "The FDA's granting of a priority review ...
Vertex Announces FDA Acceptance of New Drug Application ...crohnscolitisprofessional.org
crohnscolitisprofessional.org
— ... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. "The FDA's granting of a priority review — ... Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. "The FDA's granting of a priority review ...
Vertex Announces Possible Label Extension for CF DrugRare Disease Advisor
www.rarediseaseadvisor.com
— “Kaftrio has demonstrated unprecedented clinical benefit for eligible people living with CF,” Nia Tatsis, PhD, executive vice president — “Kaftrio has demonstrated unprecedented clinical benefit for eligible people living with CF,” Nia Tatsis, PhD, executive vice president ...
Vertex announces Carmen Bozic as CMO, Nia Tatsis as CRO VRTX - The Fly
thefly.com
Vertex announced that Car... VRTX
Vertex Pharma (VRTX) Appoints Carmen Bozic, M.D., as New Chief...
www.streetinsider.com
Vertex Pharma (VRTX) Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer.
EMA, MHRA to review Vertex' Kaftrio for children with CF |...
www.pharmasources.com
· ... also be able to access the triple combination therapy,” said Nia Tatsis, executive VP, chief regulatory and quality officer at Vertex.
Virus used to create experimental HIV vaccine | EurekAlert!
www.eurekalert.org
Leading efforts to create an HIV vaccine have hinged on the use of viruses as carriers for selected elements of the HIV virus. Recently, however, evidence has...
EU, UK Considering Expanding Kaftrio to CF Children Ages 6 and Older
cysticfibrosisnewstoday.com
· ... in broadening our access worldwide and we are pleased that we were able to file with the EMA and the MHRA in parallel,” Nia Tatsis, PhD, ...
sortiert nach Relevanz / Datum